Clinical trials: Influenza Vaccines
Influenza
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults
- Trial name
- NCT00958126
- Testing
- CSL425
- Where
- 11 sites in United States
- Volunteers
- 1,313 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge
After prophylactic vaccination with CR8020, a monoclonal antibody, subjects will be challenged with the H3N2 virus. The protective efficacy, safety, tolerability, pharmacokinetics, and potential immunogenicity will be assessed.
- Trial name
- NCT01938352
- Testing
- CR8020
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia
- Trial name
- NCT05079152
- Testing
- COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,404 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Influenza
Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age
A multi-center, open-label, escalating dose-ranging study to assess the safety, reactogenicity, and immunogenicity of four different VAX125 vaccine doses; 0.5 µg, 1.0 µg, 2.0 µg, or 3.0 µg, delivered i.m.
- Trial name
- NCT00966238
- Testing
- VAX125
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Cough
Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment
The purpose of this study is evaluate if efficacy of a combination dose of oxomemazine, guaifenesin and potassium iodate is superior than guaifenesin monotherapy in acute cough treatment.
- Trial name
- NCT01257243
- Testing
- Syrup of oxomemazine, guaifenesin and potassium iodate, Syrup of guaifenesin
- Where
- Brazil
- Volunteers
- 260 people
- Sponsor
- EMS
Acute, Uncomplicated Human Influenza
A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
The purpose of this study is to determine whether peramivir is safe and effective in the treatment of uncomplicated seasonal influenza.
- Trial name
- NCT00705406
- Testing
- Peramivir
- Where
- 123 sites in United States, Australia and 2 more
- Volunteers
- 405 people
- Sponsor
- BioCryst Pharmaceuticals
Influenza
A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults
This study will assess the Efficacy, Safety and Tolerability profile of CSL's Influenza Vaccine administered intramuscularly against laboratory-confirmed influenza illness in a population defined as being not at risk of severe…
- Trial name
- CSL's IVV (NCT00562484)
- Testing
- CSL Limited Influenza Vaccine
- Where
- 24 sites in Australia, New Zealand
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Human
A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults
The purpose of this study is to evaluate immunological efficacy and safety of GC3110B versus GCFLU Quadrivalent Inj. among healthy adults in 18 to 60 years of age.
- Trial name
- NCT02915809
- Testing
- GC3110B vaccine, GCFLU Quadrivalent Inj. vaccine
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Seasonal Influenza, Influenza
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
This study aims to evaluate the immunogenicity, by means of cell mediated immunity (CMI) and hemagglutination inhibition (HI) assay, and also the safety of a MF59C.1-adjuvanted subunit influenza vaccine compared with a…
- Conditions
- Seasonal Influenza, Influenza, Influenza Due to Unspecified Influenza Virus, Human Influenza
- Trial name
- NCT01342796
- Testing
- MF59C.1-adjuvanted subunit influenza vaccine, Sub unit, Inactivated, Influenza vaccine
- Where
- 2 sites in Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Seasonal Influenza
A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
A phase III clinical trial of the study of quadrivalent influenza vaccine developed by Sinovac Biotech will be conducted in Chinese children aged 6 to 35 months.
- Trial name
- NCT06049927
- Testing
- Quadrivalent influenza vaccine(0.25ml), Quadrivalent influenza vaccine(0.5ml), Trivalent influenza vaccine(BV)
- Where
- 5 sites in China
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell Culture Derived Influenza Vaccine in Adult Subjects.
- Trial name
- NCT01776541
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 979 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children
The purpose of this study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in healthy children 6 to 35 months of age.
- Trial name
- NCT01096056
- Testing
- Influenza vaccine GSK2186877A formulation 1, Influenza vaccine GSK2186877A formulation 2, Fluarix
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mumps, Influenza
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students
This study is a randomized, controlled, open-label phase Ⅳ clinical trial of a live attenuated mumps vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
- Trial name
- NCT06208683
- Testing
- Mumps vaccine, Live (MV), Influenza Vaccine, inactivated, quadrivlent(QIV)
- Where
- 3 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The purpose of the study is to evaluate the safety and immunogenicity of GSK Biologicals' influenza vaccine GSK2340272A.
- Trial name
- NCT00951041
- Testing
- GSK investigational vaccine GSK2340272A, GSK investigational vaccine GSK2340269A
- Where
- 3 sites in Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00538473
- Testing
- GSK Biologicals' influenza vaccine GSK576389A, Fluarix™
- Where
- Belgium
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza
Assessment of the effect reached with the different doses of AV5080 on the duration and severity of influenza symptoms based on the incidence of their resolution within 96 hours from study treatment initiation compared to…
- Trial name
- NCT05095545
- Testing
- AV5080
- Where
- 10 sites in Russia
- Volunteers
- 135 people
- Sponsor
- Viriom
Influenza
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
The purpose of this study is to demonstrate the efficacy of an investigational Vero cell-derived, trivalent, seasonal influenza vaccine to prevent infection with an influenza virus that is antigenically similar to one of the…
- Trial name
- NCT00800605
- Testing
- Vero cell-derived, trivalent, seasonal influenza vaccine
- Where
- 36 sites in United States
- Volunteers
- 7,250 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Pandemic, Avian Influenza
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
This study evaluates the immunogenicity, safety and tolerability of an H5N1 vaccine with a seasonal trivalent influenza vaccine, containing the strains recommended by WHO for the 2007 influenza season in the Southern Hemisphere.
- Trial name
- NCT00481065
- Testing
- MF59-eH5N1, eTIV_a, MF59-eH5N1 + eTIV_a
- Where
- Colombia
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Novartis
Cough
Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children
The goal of this clinical trial is to evaluate the efficacy and safety of liquid dosage form of Rengalin in the treatment of cough in acute viral upper respiratory tract infections infections in children in during the epidemic…
- Trial name
- NCT07171099
- Testing
- Rengalin
- Where
- 30 sites in Russia
- Volunteers
- 264 people
- Sponsor
- Materia Medica Holding
Influenza
Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age
The primary objective of this study is to estimate the relative efficacy and assess the safety of CAIV-T compared to TIV.
- Trial name
- NCT00128167
- Testing
- Liquid CAIV-T
- Where
- 161 sites in United States, Belgium and 6 more
- Volunteers
- 8,500 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.